Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
certified treatment centers
|
| gptkbp:approvalYear |
2017-10-18
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XL08
|
| gptkbp:blackBoxWarning |
cytokine release syndrome
neurological toxicities |
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:genericName |
gptkb:axicabtagene_ciloleucel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Yescarta (2017)
|
| gptkbp:indication |
relapsed or refractory large B-cell lymphoma
|
| gptkbp:manufacturer |
gptkb:Kite_Pharma
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells targeting CD19
|
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:parentCompany |
gptkb:Gilead_Sciences
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:storage |
cryopreserved
|
| gptkbp:target |
gptkb:CD19
|
| gptkbp:bfsParent |
gptkb:Kite_Pharma
|
| gptkbp:bfsLayer |
6
|